Skip to content

Traws Pharma, Inc.

TRAW

CIK 0001130598

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
$9.51M
+105.5% YoY Q1 May 2026
EPS Diluted (TTM)
$1.11
+102.3% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$16.99M
Q1 May 2026
Cash
$20.56M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
15.15M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings